Health Technology Review	
Technology Ref:	**HTA20016**
Technology Name:	**Caris Molecular Intelligence (CMI)**
Approvals by International Bodies:	**CE-Marked**
Company name:	**IPS Genomix SAL (Offshore)**
Agent in UAE:	**Rachel Sawan**
Email:	**Rachel.Sawan@medfronthealthcare.com**

Short Description of the Technology:	The Caris Molecular Intelligence (CMI) Profile testing service that is performed exclusively at Caris Life Sciences - USA supports oncologists in taking evidence-based treatment decisions for patients with advanced solid tumors for whom no or few standards of care exists (e.g. rare cancers, aggressive, difficult to treat, metastatic cancers refractory to standard treatment options); empirically selected treatments achieve only limited success. It is a multiplatform tumor profiling service that is comprehensive of next-generation sequencing (NGS) of DNA and RNA, immunohistochemistry (IHC) and in situ hybridization (FISH).

Health Technology Assessment Team Recommendation:	**Not Recommended**

Summary of Review:

The aim of the Caris MI Profile testing service is to identify therapies/drugs associated with potential benefit or therapies/drugs associated with potential lack of benefit in patients with advanced solid tumors for whom no or few standards of care exists. The samples shall be sent out to the Caris Life Sciences Laboratories in the US. There are similar tumor profiling available in the market with FDA approval and is more effective. Caris MI is not the best choice for comprehensive genomic profiling for cancer patients.

Advantages	Disadvantages
CE-marked	Availability of FDA approved and more clinical effective tumor profiling with supporting data in the market
Personalized therapy	Not FDA approved
No risk on patients nor the healthcare professionals	Need to send the samples out to the US
Helps in reduction in the risk of death	Not new technology
Helps in decrease the cost of ineffective treatments	Not the best choice for comprehensive tumor profiling

After studying the solution and its evidence and considering the available alternatives, the Health Technology Assessment team decided to **Not Recommend** this solution due to the availability of similar solutions that is more effective and FDA-approved used in the market.